[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_3″ last=”no” spacing=”yes” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” class=”” id=””][fusion_text]pres-1[/fusion_text][/fusion_builder_column][fusion_builder_column type=”2_3″ last=”yes” spacing=”yes” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” class=”” id=””][fusion_text]Denosumab vs Zoledronic Acid Poster Presentation
5/2012 New Orleans, LA
Stacey Harrelson, RN, CCRC
Comparing the Incidence of Acute Phase Reactions in Patients with Advanced Cancer and Bone Metastases or Multiple Myeloma Following Treatment with Denosumab or Zoledronic Acid: Results from a Combined Analysis of Three Phase 3 Randomized Trials.[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]